Table 1 Clinical-pathological characteristics of non-small-cell lung cancer patients
From: Signaling protein signature predicts clinical outcome of non-small-cell lung cancer
Variable | All patients (n = 384) | BJ cohort (n = 211) | CQ cohort (n = 173) |
|---|---|---|---|
Age | |||
 ≤60 | 151 (39.32%) | 73 (34.60%) | 78 (45.09%) |
 > 60 | 233 (60.68%) | 138 (65.40%) | 95 (54.91%) |
Gender | |||
 Male | 270 (70.31%) | 135 (63.98%) | 135 (78.03%) |
 Female | 114 (29.69%) | 76 (36.02%) | 38(21.97%) |
Smoking index (pack years) | |||
 Never smokers | 142 (36.98%) | 94 (44.55%) | 48 (27.75%) |
 Light smokers (< 20) | 41 (10.68%) | 26 (12.32%) | 15 (8.67%) |
 Heavy smokers (≥20) | 183 (47.65%) | 88 (41.71%) | 95 (54.91%) |
 Unknown | 18 (4.69%) | 3 (1.42%) | 15 (8.67%) |
Histology | |||
 Adenocarcinoma | 206 (53.65%) | 122 (57.82%) | 84 (48.55%) |
 Squamous cell carcinoma | 178 (46.35%) | 89 (42.18%) | 89 (51.45%) |
 Follow-up (months; median; IQR) | 58 (22–75) | 59 (19–74) | 56 (29–76) |
 Deaths | 175 (45.57%) | 93 (44.07%) | 82 (47.40%) |
Differentiation grade | |||
 Well | 75 (19.53%) | 45 (21.33%) | 30 (17.34%) |
 Moderate | 140 (36.46%) | 67 (31.75%) | 73 (42.20%) |
 Poor | 138 (35.94%) | 98 (46.45%) | 40 (23.12%) |
 Unknown | 31 (8.07%) | 1 (0.47%) | 30 (17.34%) |
Pathologic stage | |||
 I | 188 (48.96%) | 95 (45.02%) | 93 (53.76%) |
 II | 101 (26.30%) | 47 (22.28%) | 54 (31.21%) |
 III | 95 (24.74%) | 69 (32.70%) | 26 (15.03%) |
Adjuvant chemotherapy | |||
 No | 141 (36.72%) | 100 (47.39%) | 41 (23.70%) |
 Yes | 243 (63.28%) | 111 (52.61%) | 132 (76.30%) |